Needham Downgrades Verrica Pharmaceuticals (VRCA) to Hold
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- Wall St rises as yields ease, Moderna lifts healthcare stocks
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Deutsche Bank calls Treasury buyback doubling similar to ’operation twist’
- Marvell issues Google warrant tied to custom chip deal
- Tech selloff weighs down Wall Street as bond yields climb
- FOMC minutes from July 28-29th meeting
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
Brookline Capital Markets Downgrades Verrica Pharmaceuticals (VRCA) to Hold
October 2, 2024 10:30 AM EDTBrookline Capital Markets analyst Kemp Dolliver downgraded Verrica Pharmaceuticals (NASDAQ: VRCA) from Buy to Hold.
For an analyst ratings summary and ratings history on Verrica Pharmaceuticals click here. For more ratings news on Verrica Pharmaceuticals click here.
Shares of Verrica Pharmaceuticals closed at $1.37 yesterday.
... MoreVerrica Pharmaceuticals (VRCA) Announces Restructuring of Commercial Organization
October 2, 2024 7:32 AM EDTVerrica Pharmaceuticals Inc. (Verrica or the Company) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced a restructuring of its sales and operating teams to reduce costs and expand access to YCANTH® for the treatment of molluscum... More
